Related Experiment Video
Updated: Oct 23, 2025

Inducing Myointimal Hyperplasia Versus Atherosclerosis in Mice: An Introduction of Two Valid Models
Published on: May 14, 2014
Inhibition of Rac1 GTPase Decreases Vascular Oxidative Stress, Improves Endothelial Function, and Attenuates
Sebastian Zimmer1, Philip Roger Goody1, Matthias Oelze2
1Department of Internal Medicine II, Heart Center Bonn, University Hospital Bonn, Bonn, Germany.
Abstract:
Aims: Oxidative stress and inflammation contribute to atherogenesis. Rac1 GTPase regulates pro-oxidant NADPH oxidase activity, reactive oxygen species (ROS) formation, actin cytoskeleton organization and monocyte adhesion. We investigated the vascular effects of pharmacological inhibition of Rac1 GTPase in mice. Methods and Results: We treated wild-type and apolipoprotein E-deficient (ApoE-/-) mice with Clostridium sordellii lethal toxin (LT), a Rac1 inhibitor, and assessed vascular oxidative stress, expression and activity of involved proteins, endothelial function, macrophage infiltration, and atherosclerosis development. LT-treated wild-type mice displayed decreased vascular NADPH oxidase activity and ROS production. Therapeutic LT doses had no impact on behavior, food intake, body weight, heart rate, blood pressure, vascular and myocardial function, differential blood count, and vascular permeability. ApoE-/- mice were fed a cholesterol-rich diet and were treated with LT or vehicle. LT treatment led to decreased aortic Rac1 GTPase activity, NADPH oxidase activity and ROS production, but had no impact on expression and membrane translocation of NADPH oxidase subunits and RhoA GTPase activity. LT-treated mice showed improved aortic endothelium-dependent vasodilation, attenuated atherosclerotic lesion formation and reduced macrophage infiltration of atherosclerotic plaques. Concomitant treatment of cholesterol-fed ApoE-/- mice with LT, the specific synthetic Rac1 inhibitor NSC 23766 or simvastatin comparably reduced aortic Rac1 activity, NADPH oxidase activity, oxidative stress, endothelial dysfunction, atherosclerosis development, and macrophage infiltration. Conclusions: These findings identify an important role of the small GTPase Rac1 in atherogenesis and provide a potential target for anti-atherosclerotic therapy.
Insights
Pharmacological inhibition of Rac1 GTPase reduced oxidative stress and atherosclerosis development in mice. This suggests Rac1 is a potential therapeutic target for anti-atherosclerotic therapy.
Area of Science:
- Cardiovascular Biology
- Molecular Medicine
- Pharmacology
Background:
- Oxidative stress and inflammation are key drivers of atherosclerosis.
- Rac1 GTPase influences NADPH oxidase activity, ROS production, and monocyte adhesion, all relevant to atherogenesis.
Purpose of the Study:
- To investigate the vascular effects of pharmacological Rac1 GTPase inhibition in mouse models.
- To determine if inhibiting Rac1 can mitigate atherosclerosis development and related vascular dysfunction.
Main Methods:
- Wild-type and apolipoprotein E-deficient (ApoE-/-) mice were treated with Clostridium sordellii lethal toxin (LT), a Rac1 inhibitor.
- Vascular oxidative stress, protein activity, endothelial function, macrophage infiltration, and atherosclerosis were assessed.
- Comparisons were made with vehicle-treated and simvastatin-treated groups.
Main Results:
- LT treatment decreased vascular NADPH oxidase activity and ROS production in wild-type mice without adverse effects.
- In ApoE-/- mice, LT reduced aortic Rac1 GTPase and NADPH oxidase activity, and ROS production.
- LT treatment improved endothelial vasodilation, reduced atherosclerotic lesions, and decreased macrophage infiltration.
Conclusions:
- Rac1 GTPase plays a significant role in the development of atherosclerosis.
- Pharmacological inhibition of Rac1, as demonstrated with LT, offers a potential therapeutic strategy for anti-atherosclerotic treatment.

